Sight Sciences wins FDA clearance for OMNI Ultra glaucoma device

What happened

Sight Sciences, Inc. (Nasdaq: SGHT) said on August 4, 2026 that it received 510(k) clearance from the US Food and Drug Administration for its OMNI Ultra Surgical System, according to the company's announcement distributed via GlobeNewswire.

The clearance covers use of the device for canaloplasty followed by trabeculotomy in adults with primary open-angle glaucoma. The company said it is the first such device cleared for single-pass circumferential canaloplasty, and that it plans to begin US commercial launch in the fourth quarter of 2026.

Sight Sciences is a small-cap eyecare technology company that sells surgical and interventional devices for glaucoma and dry eye. Its shares closed at $8.14 on August 6, up 1.69% from the prior close of $8.005, according to the price data.

The product and the procedures

The OMNI Surgical System is the company's existing device used in minimally invasive glaucoma surgery, or MIGS — a category of procedures that treat glaucoma through small incisions rather than the larger operations used in traditional glaucoma surgery.

Canaloplasty and trabeculotomy are two parts of the eye's drainage pathway targeted in these procedures. Canaloplasty widens Schlemm's canal, the circular channel that drains fluid from the front of the eye; trabeculotomy cuts through the trabecular meshwork, the tissue that regulates flow into that canal. Both are intended to lower intraocular pressure, the buildup of fluid pressure inside the eye that damages the optic nerve in glaucoma.

Sight Sciences describes OMNI Ultra as performing both steps in a single pass, and says the FDA clearance makes it the first device cleared for single-pass circumferential canaloplasty. The company has not said in the announcement how much the device will cost or how many procedures it expects.

Q2 results and guidance

Separately, Sight Sciences reported second-quarter 2026 financial results on August 5 and raised its full-year 2026 revenue guidance, according to summaries of the release carried by TipRanks and Zacks. The price data provided does not include the company's reported revenue figures.

What this means

A 510(k) is the most common path a medical device takes to US market authorization. Rather than running new clinical trials from scratch, a company submits evidence that its device is "substantially equivalent" to a legally marketed predicate device — similar in intended use and technology. Clearance is not the same as approval: the FDA's stricter premarket approval (PMA) pathway applies to higher-risk devices. A 510(k) clearance lets a company market the device for the specific uses listed in the clearance.

That distinction matters here because the clearance defines exactly what Sight Sciences may claim and sell: canaloplasty followed by trabeculotomy in adult primary open-angle glaucoma — not glaucoma generally, and not other forms of the disease.

For a company of Sight Sciences' size, whose interventional glaucoma business is its central growth story, a new cleared device expands what its sales force can offer in the same procedure category its existing OMNI system already serves. The company has said launch is planned for the fourth quarter of 2026, but it has not disclosed pricing, reimbursement status, or volume expectations for the new system in the announcement.

One caution on sourcing: no SEC filing accompanies this development in the material provided, so nothing here is drawn from a regulatory filing, and the earnings detail for the second quarter is described only through third-party summaries rather than the underlying release figures.